An official website of the United States government
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Trial Status: complete
The goal of this clinical study is to learn more about the study drug, sacituzumab
govitecan-hziy (SG), and how safe it is in participants with metastatic cancer (cancer
that has spread).
Inclusion Criteria
Receiving ongoing treatment with sacituzumab govitecan in a Gilead (previously Immunomedics)-sponsored parent study.
Continuing to receive clinical benefit from sacituzumab govitecan-hziy therapy. Key
Exclusion Criteria
Females who are pregnant or lactating.
Initiated therapy with another cancer therapeutic agent since receiving last dose of study drug on the parent study in which they participated.
Experienced a toxicity from sacituzumab govitecan-hziy that resulted in permanent discontinuation of therapy.
Have other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations. Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04319198.
